{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:43:27Z","timestamp":1768887807801,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-02234-5","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:18:38Z","timestamp":1765779518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strengthening inferential studies in the FDA Sentinel initiative: results from a methodological demonstration project"],"prefix":"10.1038","volume":"9","author":[{"given":"Rishi J.","family":"Desai","sequence":"first","affiliation":[]},{"given":"Janick","family":"Weberpals","sequence":"additional","affiliation":[]},{"given":"Haritha","family":"Pillai","sequence":"additional","affiliation":[]},{"given":"Adebola","family":"Ajao","sequence":"additional","affiliation":[]},{"given":"Mukund","family":"Desibhatla","sequence":"additional","affiliation":[]},{"given":"Rebecca","family":"Hawrusik","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 J.","family":"Hern\u00e1ndez-Mu\u00f1oz","sequence":"additional","affiliation":[]},{"given":"Chanelle","family":"Jones","sequence":"additional","affiliation":[]},{"given":"Jamal T.","family":"Jones","sequence":"additional","affiliation":[]},{"given":"Joyce","family":"Lii","sequence":"additional","affiliation":[]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[]},{"given":"Jennifer G.","family":"Lyons","sequence":"additional","affiliation":[]},{"given":"Ryan","family":"Schoeplein","sequence":"additional","affiliation":[]},{"given":"Fatma M.","family":"Shebl","sequence":"additional","affiliation":[]},{"given":"Sengwee","family":"Toh","sequence":"additional","affiliation":[]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2234_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cpt.320","volume":"99","author":"R Ball","year":"2016","unstructured":"Ball, R., Robb, M., Anderson, S. A. & Dal Pan, G. The FDA\u2019s sentinel initiative\u2014a comprehensive approach to medical product surveillance. Clin. Pharm. Ther. 99, 265\u2013268 (2016).","journal-title":"Clin. Pharm. Ther."},{"key":"2234_CR2","doi-asserted-by":"publisher","unstructured":"Maro, J. C. et al. Six years of the US Food and Drug Administration\u2019s postmarket active risk identification and analysis system in the Sentinel initiative: implications for real world evidence generation. Clin. Pharmacol. Ther. https:\/\/doi.org\/10.1002\/cpt.2979 (2023).","DOI":"10.1002\/cpt.2979"},{"key":"2234_CR3","doi-asserted-by":"publisher","unstructured":"Desai, R. J. et al. The FDA Sentinel Real World Evidence Data Enterprise (RWE-DE). Pharmacoepidemiol. Drug Saf. https:\/\/doi.org\/10.1002\/pds.70028 (2024).","DOI":"10.1002\/pds.70028"},{"key":"2234_CR4","doi-asserted-by":"publisher","unstructured":"Schneeweiss, S., Desai, R. J. & Ball, R. Invited commentary: a future of data-rich pharmacoepidemiology studies- transitioning to large-scale linked EHR+claims data. Am. J. Epidemiol. https:\/\/doi.org\/10.1093\/aje\/kwae226 (2024).","DOI":"10.1093\/aje\/kwae226"},{"key":"2234_CR5","unstructured":"Moores, K., Gilchrist, B., Abrams, T. & Carnahan, R. Mini-Sentinel Systematic Evaluation of Health Outcome of Interest Definitions for Studies Using Administrative Data\u2014Pancreatitis Report (2011)."},{"key":"2234_CR6","doi-asserted-by":"publisher","unstructured":"Floyd, J. S. et al. Validation of acute pancreatitis among adults in an integrated healthcare system. Epidemiology. https:\/\/doi.org\/10.1097\/EDE.0000000000001541 (2023).","DOI":"10.1097\/EDE.0000000000001541"},{"key":"2234_CR7","unstructured":"Sentinel Initiative. Advancing Scalable Natural Language Processing Approaches for Unstructured Electronic Health Record Data. Available at https:\/\/www.sentinelinitiative.org\/methods-data-tools\/methods\/advancing-scalable-natural-language-processing-approaches-unstructured (2021)."},{"key":"2234_CR8","doi-asserted-by":"crossref","unstructured":"Weberpals, J. et al. A principled approach to characterize and analyze partially observed confounder data from electronic health records. Clin. Epidemiol. 16, 329\u2013343 (2024).","DOI":"10.2147\/CLEP.S436131"},{"key":"2234_CR9","doi-asserted-by":"publisher","unstructured":"Walsh, C. G. et al. Scalable incident detection via natural language processing and probabilistic language models. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-024-72756-7 (2024).","DOI":"10.1038\/s41598-024-72756-7"},{"key":"2234_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/aje\/kwac182","volume":"192","author":"DS Carrell","year":"2023","unstructured":"Carrell, D. S. et al. Improving methods of identifying anaphylaxis for medical product safety surveillance using natural language processing and machine learning. Am. J. Epidemiol. 192, 283\u2013295 (2023).","journal-title":"Am. J. Epidemiol."},{"key":"2234_CR11","doi-asserted-by":"publisher","unstructured":"Weberpals, J. et al. smdi: an R package to perform structural missing data investigations on partially observed confounders in real-world evidence studies. JAMIA Open. https:\/\/doi.org\/10.1093\/jamiaopen\/ooae008 (2024).","DOI":"10.1093\/jamiaopen\/ooae008"},{"key":"2234_CR12","doi-asserted-by":"publisher","unstructured":"Williamson, B. D. et al. Assessing treatment effects in observational data with missing confounders: a comparative study of practical doubly-robust and traditional missing data methods. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2412.15012 (2024).","DOI":"10.48550\/arXiv.2412.15012"},{"key":"2234_CR13","unstructured":"Stayner, L. et al. Statistical Methods in Cancer Research Volume V: Bias Assessment in Case\u2013Control and Cohort Studies for Hazard Identification (International Agency for Research on Cancer, 2024)."},{"key":"2234_CR14","doi-asserted-by":"publisher","unstructured":"Desai, R. J. et al. Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA Sentinel Innovation Center. BMJ. https:\/\/doi.org\/10.1136\/bmj-2023-076460 (2024).","DOI":"10.1136\/bmj-2023-076460"},{"key":"2234_CR15","doi-asserted-by":"publisher","unstructured":"Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R. & Butler, P. C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.018 (2011).","DOI":"10.1053\/j.gastro.2011.02.018"},{"key":"2234_CR16","unstructured":"Sentinel Initiative. Risk of acute pancreatitis following SGLT2 inhibitor use in patients with type 2 diabetes mellitus. https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/documents\/Risk-of-Acute-Pancreatitis-Following-SGLT2-Inhibitor-Use-in-Patients-with-Type-2-Diabetes-Mellitus_Study-Protocol_19September2024.pdf (2024)."},{"key":"2234_CR17","doi-asserted-by":"publisher","unstructured":"Sodhi, M., Rezaeianzadeh, R., Kezouh, A. & Etminan, M. GLP-1 agonists and gastrointestinal adverse events. JAMA. https:\/\/doi.org\/10.1001\/jama.2023.19574 (2023).","DOI":"10.1001\/jama.2023.19574"},{"key":"2234_CR18","doi-asserted-by":"publisher","unstructured":"Cao, C. et al. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine https:\/\/doi.org\/10.1007\/s12020-020-02223-6 (2020).","DOI":"10.1007\/s12020-020-02223-6"},{"key":"2234_CR19","doi-asserted-by":"publisher","unstructured":"Wang, H. et al. Hemodialysis and risk of acute pancreatitis: a systematic review and meta-analysis. Pancreatology. https:\/\/doi.org\/10.1016\/j.pan.2020.11.004 (2021).","DOI":"10.1016\/j.pan.2020.11.004"},{"key":"2234_CR20","doi-asserted-by":"publisher","unstructured":"Dassopoulos, T. & Ehrenpreis, E. D. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am. J. Med. https:\/\/doi.org\/10.1016\/S0002-9343(99)00169-2 (1999).","DOI":"10.1016\/S0002-9343(99)00169-2"},{"key":"2234_CR21","first-page":"980","volume":"73","author":"DH Kim","year":"2018","unstructured":"Kim, D. H. et al. Measuring frailty in medicare data: development and validation of a claims-based frailty index. J. Gerontology: Ser. A 73, 980\u2013987 (2018).","journal-title":"J. Gerontology: Ser. A"},{"key":"2234_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","volume":"64","author":"JJ Gagne","year":"2011","unstructured":"Gagne, J. J., Glynn, R. J., Avorn, J., Levin, R. & Schneeweiss, S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J. Clin. Epidemiol. 64, 749\u2013759 (2011).","journal-title":"J. Clin. Epidemiol."},{"key":"2234_CR23","doi-asserted-by":"publisher","unstructured":"Desai, R. J., Rothman, K. J., Bateman, B. T., Hernandez-Diaz, S. & Huybrechts, K. F. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology. https:\/\/doi.org\/10.1097\/EDE.0000000000000595 (2017).","DOI":"10.1097\/EDE.0000000000000595"},{"key":"2234_CR24","doi-asserted-by":"crossref","unstructured":"Cafri, G. Why we should be prioritizing the average treatment effect on the treated over other Estimands when evaluating drug and device safety. Am. J. Epidemiol. 194, 3602\u20133608 (2025).","DOI":"10.1093\/aje\/kwaf175"},{"key":"2234_CR25","doi-asserted-by":"crossref","unstructured":"Desai R. J., Franklin J. M. Alternative approaches for confounding adjustment in observational studies using weighting based on thepropensity score: a primer for practitioners. BMJ 367, l5657 (2019).","DOI":"10.1136\/bmj.l5657"},{"key":"2234_CR26","doi-asserted-by":"publisher","unstructured":"Austin, P. C., Lee, D. S. & Fine, J. P. Introduction to the analysis of survival data in the presence of competing risks. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017719 (2016).","DOI":"10.1161\/CIRCULATIONAHA.115.017719"},{"key":"2234_CR27","doi-asserted-by":"publisher","unstructured":"Pishgar, F., Greifer, N., Leyrat, C. & Stuart, E. MatchThem: Matching and Weighting after Multiple Imputation. The R. Journal. https:\/\/doi.org\/10.32614\/RJ-2021-073, https:\/\/journal.r-project.org\/archive\/2021\/RJ-2021-073\/ (2021).","DOI":"10.32614\/RJ-2021-073"},{"key":"2234_CR28","doi-asserted-by":"crossref","unstructured":"Rubin, D. B. Multiple imputation for nonresponse in surveys. Wiley Series in Probability and Statistics (1987).","DOI":"10.1002\/9780470316696"},{"key":"2234_CR29","doi-asserted-by":"publisher","unstructured":"Shi, X., Miao, W. & Tchetgen Tchetgen, E. A selective review of negative control methods in epidemiology. Curr. Epidemiol. Rep. https:\/\/doi.org\/10.1007\/s40471-020-00243-4 (2020).","DOI":"10.1007\/s40471-020-00243-4"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02234-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:39:01Z","timestamp":1768840741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02234-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-02234-5","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Desai reports serving as Principal Investigator on investigator-initiated grants to the Brigham and Women\u2019s Hospital from Novartis, Vertex, and Bayer on unrelated projects. Dr. Schneeweiss is co-principal investigator of an investigator-initiated grant to the Brigham and Women\u2019s Hospital from Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion Inc., a software manufacturer of which he owns equity. His interests were declared, reviewed, and approved by the Brigham and Women\u2019s Hospital and MGB HealthCare System in accordance with their institutional compliance policies. Dr. Weberpals is now an employee of AstraZeneca and owns stocks in AstraZeneca. Other authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}